ArticleHuman vaccines & immunotherapeutics2026
Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing advanced urothelial cancer.
Zuojuan Xiang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.